lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - Æxlishemjandi lyf - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
omeprazol actavis magasýruþolið hart hylki 40 mg
actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 40 mg
omeprazol actavis magasýruþolið hart hylki 20 mg
actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 20 mg
omeprazol actavis magasýruþolið hart hylki 10 mg
actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 10 mg
nexium (lyfjaver) magasýruþolin tafla 40 mg
lyfjaver ehf. - esomeprazolum - magasýruþolin tafla - 40 mg
esomeprazol actavis magasýruþolin tafla 40 mg
actavis group ptc ehf. - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg
esomeprazol actavis magasýruþolin tafla 20 mg
actavis group ptc ehf. - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg
esomeprazol krka magasýruþolið hart hylki 20 mg
krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 20 mg
esomeprazol krka magasýruþolið hart hylki 40 mg
krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 40 mg